Schedule
Thursday, May 28
8 - 5PM	Registration
10 - 5PM	Personnel Placement
10 - 5PM	Exhibits and Contributed Poster Presentations in Exhibit Hall
8 - 10AM	Second General Session
	"The Role of Government in Outcomes Research" Moderator: Louis Morris PhD, Senior Vice President, PPR Inc. Keynote Speaker: John Eisenberg MD, MBA, Administrator, Agency for Health Care Policy and Research Keynote Address: "The Role of Government in Outcomes Research" "Update on the FDA Policy concerning the FDA Modernization Act of 1997" Laurie B. Burke RPh, MPH, Epidemiologist, Food and Drug Administration "Implementation Issues of the FDA Modernization Act of 1997" William W. Vodra, Esquire, Arnold and Porter
10:30 - 12PM	Contributed Podium Presentations
	"ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH & NEUROLOGIC DISORDERS" TREATMENT CHOICE AND THE INCIDENCE AND ECONOMIC INTENSITY Of Hospital Inpatient use by Depressed Patients Croghan TW, Kniesner TJJ, Melfi CA, Klein EG, Eli Lilly and Company, Indianapolis, IN, USA. MEDICAL COSTS OF EFFEXOR® VERSUS TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANT THERAPY AFTER SWITCHING FROM SELECTIVE SEROTONIN REUPTAKE INHIBITORS Griffiths RI, Sullivan EM, Frank RG, Herbert RJ, Strauss MJ, Goldman HH, Covance Health Economics and Outcomes Services Inc., Washington, DC, USA. COST EFFECTIVENESS EVALUATION OF NEW ANTIPSYCHOTICS Launois R1, Knapp M2, Graf VD??? Schulenburg M3, Toumi M4, 1Paris North University, Paris, France, 2London School of Economics, London, Great Britain, 3Universität Hannover, Hannover, Germany, 4Lundbeck, Denmark COMPARISON OF STANDARD GAMBLE, TIME TRADE OFF, AND VISUAL ANALOG SCALE SCORES FOR HYPOTHETICAL STROKE HEALTH STATES USING A COMPUTER BASED PROGRAM Namjoshi MA, Taylor TN, The University of Iowa, Iowa City, IA, USA. CHANGES IN SEXUAL FUNCTION AND BOTHER IN MEN TREATED FOR PROSTATE CANCER: RESULTS FROM THE CaPSURE® DATABASE. Flanders S1, Henning JM1, Lubeck DP2, Pasta DJ2, Stoddard ML2, Litwin MS3, 1TAP Holdings Inc., Deerfield, IL, USA; 2Technology Assessment Group, San Francisco, CA, USA; 3UCLA, Department of Urology, Los Angeles, CA, USA. MEDICAL AND ECONOMIC RELEVANCE OF SCREENING OF STROKE RISK BY EMPLOYEES Hansen N, Lipinski J, Rappenhöner B, Bachinger A, Rychlik R. Institute of Empirical Health Economics, Odenthal, Germany "ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE" COST OF ITALIAN HYPERTENSIVE PATIENT: A FEASIBILITY STUDY FROM THE PANDORA PROJECT Berto P1, Degli Esposti E2, Buda S3, Sturani A2, Reggio S4, 1PBE consultants, Verona; 2SM delle Croci Hospital, Ravenna; 3Clicon Software, Ravenna; 4Pfizer Italiana, Roma, Italy DEVELOPMENT AND CROSS-VALIDATION OF A COMORBIDITY INDEX FOR A STROKE POPULATION. Ricci JF, Martin BC, College of Pharmacy, University of Georgia, Athens, GA, USA. EVALUATION OF THE COSTS OF CORONARY HEART DISEASE IN BELGIUM Annemans L1,2, De Backer W2, Van Rompay W1, Closon MC3, 1HEDM, Belgium; 2Rijks Universiteit Gent, Belgium, 3Université Catolique Louvain, Belgium IN-HOSPITAL SURVIVAL AMONG PATIENTS WHO RECEIVED EITHER AMRINONE, DOBUTAMINE, OR MILRINONE Weycker DA, Simons WR, Department of Health Economics, Sanofi Pharmaceuticals, New York, NY, USA. PREVENTING CARDIOVASCULAR DISEASE: IS PRIMARY PREVENTION WITH PRAVASTATIN WORTH THE MONEY? Caro JJ1, Payne K2, Klittich WS1, Getsios D2, Shepherd J3, Pettitt D4, WOSCOPS Economic Analysis Committee. 1Caro Research, Boston, USA, 2Caro Research Montreal, Montreal, Canada, 3University of Glasgow, Glasgow, Scotland, 4Bristol-Myers Squibb, Princeton, NJ, USA. TORSEMIDE AND FUROSEMIDE IN THE TREATMENT OF THE EDEMA OF HEART FAILURE: INTERIM RESULTS OF A RANDOMIZED EFFECTIVENESS TRIAL. Murray M1, Stroupe K2, Pierson W3, Heyman E3, Minick S4, Tierney W2,4, Brater C4 1Purdue University School of Pharmacy, Indianapolis, IN, USA, 2Regenstrief Institute, Indianapolis, IN, USA; 3Boehringer-Mannheim Pharmaceuticals, Gaithersburg, MD, USA; 4Indiana University School of Medicine, Indianapolis, IN, USA.
1 - 3:15PM	Contributed Workshops (3 sessions @ 35 minutes)
	See ­ CONTRIBUTED WORKSHOPS Section
3:30 - 5PM	Third General Session
	"The Role of the Patient in Health Care Decision-making" Moderator: Peter Ubel MD, Assistant Professor, University of Pennsylvania, Leonard Davis Institute Keynote Speaker: Norman Daniels PhD, Professor of Medical Ethics, Tufts University Keynote Address: "The Legitimacy of Limit Setting: Political and Patient Obstacles to the Use of Outcomes Research in Decision Making" "Can Patient Centered Decision Making Yield Cost-Effective Care " Robert Nease Jr. PhD, Assistant Professor, Washington University School of Medicine "Health Care Decision Making: Its in the Consumers' Hands" Linda Gladner, Executive Director, National Consumers League
5 - 6PM	ISPOR Business Meeting
6 - 7PM	Exhibitors Open House and Reception